SFRP1 and prostate carcinoma: Promisingly, co-treatment with enzalutamide and TRC105 (a partially humanized CD105 neutralizing antibody) is reported to suppress SFRP1 expression in 22Rv1 prostate cancer cells, circumventing neuroendocrine differentiation and suppressing CRPC progression in a xenograft mouse model that did not respond to either monotherapy [6].